FORT WORTH, Texas, June 30 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), has announced the signing of a commission based, sales agreement for its wound care product, CellerateRx(R), with EWA Government Systems, Inc. (EWA GSI). This agreement follows discussions and demonstrations, and validates that CellerateRx is destined to play a vital role in international wound management. CellerateRx patented collagen fragments (CRX) are a fraction of the size of native collagen molecules found in other products, and provide the benefits of collagen to the body immediately. The product provides unprecedented range of use, cost savings and patient friendliness.
"We believe that this agreement is a huge step for us, and that EWA GSI's capabilities in marketing our product represent a strong alliance with a major distributor that facilitates the needs of government entities," stated Scott Haire, CEO of Wound Management Technologies, Inc.
"While we are excited about the revenue opportunities, we are appreciative of EWA GSI's recognition that CellerateRx will play a key role in assisting physicians in wound management both domestically and now in the international markets as well," continued Haire.
The agreement grants to EWA GSI the right to market both the gel and powder forms of CellerateRx and will be compensated strictly on a commission basis for products sold.
About EWA Government Systems, Inc.:
EWA Government Systems, Inc. (EWA GSI) provides the highest quality products and services across a broad range of technology and engineering specialties to a variety of industries including national defense, the Federal Government, law enforcement, emergency response, healthcare, and entertainment. They also provide comprehensive analyses, engineering, and management services to the DoD community and to Federal and Civil agencies. EWA GSI also supports the Center for National Response.
|SOURCE Wound Management Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved